Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group

References

• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Gimsing P, Holmström MO, Klausen TW, et al. The Danish National Multiple Myeloma Registry. Clin Epidemiol. 2016;25:583–587.
   Google Scholar
• Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83(6):1062–1068.
   PubMed Web of Science ®Google Scholar
• Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group. Leukemia. 2013;27:780–791.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192.
   PubMed Web of Science ®Google Scholar
• Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer. 2009;115(24):5734–5739.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(6):907–912.
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–1052.
   PubMed Web of Science ®Google Scholar
• Garcıa-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(3):1032–1037.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Roussel M, Campion L, et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia. 2012;26(1):158–159.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the intergroupe francophone du myelome and the groupe franc ̧ais de cytogenetique hematolo. Blood. 2001;97:822–825.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Yeung J, et al. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009;33(2):259–262.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kryukov F, Rihova L, et al. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015;95(1):16–26.
   PubMed Web of Science ®Google Scholar
• Peña C, Riva E, Schutz N, et al. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leuk Lymphoma. 2020;61(13):3112–3119.
   PubMed Web of Science ®Google Scholar
• Riva E, Schütz N, Peña C, et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Ann Hematol. 2020;99(5):1025–1030.
   PubMed Web of Science ®Google Scholar
• Yan W, Fan H, Xu J, et al. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria. Leuk Lymphoma. 2022;12:1–10.
   Google Scholar
• Cazaubiel T, Leleu X, Perrot A, et al. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood. 2022;139(17):2666–2672.
   PubMed Web of Science ®Google Scholar
• Roy T, An JB, Doucette K, et al. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. Leuk Lymphoma. 2022;63(3):759–761.
   PubMed Web of Science ®Google Scholar
• Katodritou E, Terpos E, Delimpasi S, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018;8(3):31.
   PubMedGoogle Scholar
• Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with total therapy protocols. Leukemia. 2012;26(11):2398–2405.
   PubMed Web of Science ®Google Scholar
• Jurczyszyn A, Radocha J, Davila J, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018;180(6):831–839.
   PubMed Web of Science ®Google Scholar
• Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the intergroupe francophone du myélome. J Clin Oncol. 2016;34(18):2125–2132.
   PubMed Web of Science ®Google Scholar
• Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28(1):222–225.
   PubMed Web of Science ®Google Scholar
• Tuazon SA, Holmberg LA, Nadeem O, et al. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021;11(2):23.
   PubMed Web of Science ®Google Scholar
• Gowin K, Skerget S, Keats JJ, et al. Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res. 2021;111:106687.
   PubMed Web of Science ®Google Scholar
• Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95(5):804–809.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26:1091–1097.
   PubMed Web of Science ®Google Scholar
• Lawless S, Iacobelli S, Knelange NS, et al. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling. Haematologica. 2022 Jun 30. doi: 10.3324/haematol.2021.280568.
   Google Scholar
• Brink M, Visser O, Zweegman S, et al. First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. Blood Cancer J. 2021;11(2):22.
   PubMed Web of Science ®Google Scholar
• Ge X, Meng W, Wang W, et al. Causes of death in primary plasma cell leukemia differ from multiple myeloma: a STROBE-compliant descriptive study based on SEER database. Medicine. 2022;101(29):e29578.
   PubMed Web of Science ®Google Scholar